http://www.cnr.it/ontology/cnr/individuo/prodotto/ID23844

Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome (Articolo in rivista)

Type

Prodotto della ricerca (Classe)
Articolo in rivista (Classe)

Label

Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome (Articolo in rivista) (literal)

Anno

2006-01-01T00:00:00+01:00 (literal)

Alternative label

Berria R.; Gastaldelli A.; Lucidi S.; Belfort R.; De Filippis E.; Easton C.; Brytzki R.; Kusi K.; Jovanovic L.; Defronzo R. A. (2006)
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome
in Clinical pharmacology and therapeutics
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Berria R.; Gastaldelli A.; Lucidi S.; Belfort R.; De Filippis E.; Easton C.; Brytzki R.; Kusi K.; Jovanovic L.; Defronzo R. A. (literal)

Pagina inizio

105 (literal)

Pagina fine

114 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

http://www.ncbi.nlm.nih.gov/pubmed/16890572 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

80 (literal)

Rivista

Clinical pharmacology and therapeutics (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

In: Clinical Pharmacology & Therapeutics, vol. 80 (02) pp. 105-114. American Society for Clinical Pharmacology, 2006. (literal)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Division of Diabetes, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA (literal)

Titolo

Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome (literal)

Abstract

Thiazolidinediones have gained widespread use for the treatment of type 2 diabetes mellitus and other insulin resistance states, including polycystic ovary syndrome (PCOS). In thiazolidinedione-treated patients a small reduction in hemoglobin and hematocrit levels often is observed, and this generally has been attributed to fluid retention. Because testosterone is a hematopoietic hormone, we investigated whether a reduction in plasma free testosterone concentration was associated with the decrease in hemoglobin and hematocrit levels in 22 nondiabetic women (9 with normal glucose tolerance and 13 with impaired glucose tolerance; mean age, 29 +/- 5 years; mean body mass index, 35.6 +/- 5.8 kg/m2) with PCOS who were treated with pioglitazone, 45 mg/d. Before treatment and after 4 months, subjects underwent an oral glucose tolerance test and measurement of total body water content with bioimpedance. Plasma testosterone, androstenedione, dehydroepiandrosterone sulfate, hemoglobin, and hematocrit levels were evaluated at baseline and every month for 4 months. The fasting plasma glucose concentration (98 +/- 9 mg/dL) was unchanged after pioglitazone treatment, whereas the 2-hour plasma glucose concentration declined from 146 +/- 41 to 119 +/- 20 mg/dL (P = .002). Both the free androgen index and the free testosterone levels calculated according to Vermeulen et al decreased significantly (from 14.4 +/- 7.1 to 10.6 +/- 7.8 [P = .02] and from 59.4 +/- 23.4 to 46.6 +/- 23.3 [P = .03], respectively). The plasma androstenedione level declined from 259 +/- 134 to 190 +/- 109 ng/dL (P = .01), whereas the dehydroepiandrosterone sulfate level did not change significantly (from 139 +/- 90 to 127 +/- 84 mug/dL, P = .2 [not significant]). The levels of both hemoglobin (from 13.6 +/- 1.0 to 12.8 +/- 1.1 g/dL, P = .0002) and hematocrit (from 39.7% +/- 2.2% to 37.9% +/- 2.7%, P = .002) fell slightly after 4 months of pioglitazone administration. Collectively, before and after pioglitazone administration, the plasma free testosterone level according to Vermeulen et al correlated positively with the levels of hemoglobin (r = 0.49, P .0001) and hematocrit (r (literal)

Prodotto di